These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma. Zarrabi K; Wu S Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188 [TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy for renal cell carcinoma - current status]. Grimm MO; Foller S Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Gill D; Hahn AW; Sonpavde G; Agarwal N Hum Vaccin Immunother; 2016 Dec; 12(12):2997-3004. PubMed ID: 27494417 [TBL] [Abstract][Full Text] [Related]
5. Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside. Weinstock M; McDermott DF Am Soc Clin Oncol Educ Book; 2015; ():e291-7. PubMed ID: 25993188 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. Liu KG; Gupta S; Goel S Oncotarget; 2017 Mar; 8(10):17313-17327. PubMed ID: 28061473 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence? Giuliani J; Drudi F Cancer Biother Radiopharm; 2012 Oct; 27(8):513-8. PubMed ID: 22738404 [TBL] [Abstract][Full Text] [Related]
8. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma. Zahoor H; Rini BI Expert Opin Emerg Drugs; 2016 Dec; 21(4):431-440. PubMed ID: 27690664 [TBL] [Abstract][Full Text] [Related]
9. Overview of current and future systemic therapy for metastatic renal cell carcinoma. Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031 [TBL] [Abstract][Full Text] [Related]
10. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions. Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639 [TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. Ornstein MC; Rini BI Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724 [TBL] [Abstract][Full Text] [Related]
12. New immunotherapy in the treatment of advanced renal cancer. Muto A; Gridelli C Expert Opin Emerg Drugs; 2019 Dec; 24(4):233-237. PubMed ID: 31751164 [No Abstract] [Full Text] [Related]
13. Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies. Thomas JS; Kabbinavar F Crit Rev Oncol Hematol; 2015 Dec; 96(3):527-33. PubMed ID: 26299335 [TBL] [Abstract][Full Text] [Related]
14. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. Oudard S; Elaidi RT Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686 [TBL] [Abstract][Full Text] [Related]
15. Novel immunotherapy in metastatic renal cell carcinoma. Cho YH; Kim MS; Chung HS; Hwang EC Investig Clin Urol; 2017 Jul; 58(4):220-227. PubMed ID: 28681030 [TBL] [Abstract][Full Text] [Related]
16. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma. Schmidinger M Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250 [TBL] [Abstract][Full Text] [Related]
17. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Atkins MB; Tannir NM Cancer Treat Rev; 2018 Nov; 70():127-137. PubMed ID: 30173085 [TBL] [Abstract][Full Text] [Related]